View More Recent Stories
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Sanofi (SNY) Appoints Jean-Paul Kress to its Board
-
TD Cowen Reiterates Hold Rating on Sanofi-Aventis (SNY) as 'Duvakitug Shows Strong Topline Data'
-
Teva (TEVA) and Sanofi (SNY) Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
-
Could Moderna stock be due for rally in 2025? Jefferies weighs in
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY), 'Top Pick Into 2025'
-
Sanofi (SNY) Plans To Change Hospital Drug-discount Program - WSJ
-
Sanofi (SNY) Tops Q3 EPS by 88c; offers guidance
-
Pai Partners Said To Raise Offer By EUR200M For Sanofi's (SNY) OTC Unit - Bloomberg
-
CD&R Is Said To Plan Measures To Ease Concerns On Sanofi (SNY) Deal - Bloomberg
-
Sanofi (SNY) confirms discussions to sell a controlling stake in Opella to CD&R
-
CD&R Said To Near EUR15b Deal For Sanofi’s (SNY) Consumer Health Unit - Bloomberg
-
Regeneron (REGN): Dupixent Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease
-
Sanofi (SNY) Said to Get Binding Bids From CR&R, PAI for Consumer Arm - Bloomberg
-
Ventyx Biosciences (VTYX) Announces $27M Strategic Investment from Sanofi (SNY)
-
Citi says this European pharma stock could surge to €130
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR130 at Citi, sees 'a highly attractive risk-reward'
-
Regeneron (REGN): Dupixent Approved in U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
-
Sanofi (SNY), RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare Cancers
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR115 at Berenberg
-
Pai Is Said In Talks With Adia, Gic To Back Bid For Sanofi (SNY) OTC - Bloomberg
-
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
-
Sanofi (SNY) Tops Q2 EPS by 84c; offers guidance
-
Sanofi’s (SNY) Consumer Arm Said To Draw Bids From Advent, PAI, CD&R - Bloomberg
-
This pharma stock is a top large cap pick for Q3 at Stifel
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR111 at Stifel
-
Sanofi (SNY) Talking To Private Equity For Sale Of Consumer Arm: CEO - Bloomberg
-
Sanofi (SNY) Nearing Decision to Invest EUR 1.3B-1.5B in Insulin Production in Frankfurt - Reuters
-
Vigil Neuroscience (VIGL) Announces $40M Investment from Sanofi (SNY) at $7.44/sh
-
Increasing unusual call option volume: ZI SNY IR XLC BYD ALNY IONS FTAI
-
Sanofi (SNY) said to seek bids for $20B consumer arm by mid-July - Bloomberg

